• November 13, 2019

Ningbo Tai Kang Medical Technology Co., Ltd Announces Global Licensing Agreement With AstraZeneca - Odessa American: Business

e-Edition Subscribe

Ningbo Tai Kang Medical Technology Co., Ltd Announces Global Licensing Agreement With AstraZeneca

Font Size:
Default font size
Larger font size

Posted: Friday, November 8, 2019 8:01 am | Updated: 8:32 am, Fri Nov 8, 2019.

NINGBO, China--(BUSINESS WIRE)--Nov 8, 2019--

Ningbo Tai Kang Medical Technology Co. Ltd. announced today that it has entered into a licensing agreement with AstraZeneca. Tai Kang has been granted the exclusive global rights to further develop and commercialize AZD3229, a small molecule KIT inhibitor that is active against primary, secondary and resistant KIT and PDGFR α mutations observed in gastrointestinal stromal tumor (GIST). The broad inhibitory activity over a spectrum of KIT and PDGFRα mutations and biochemical selectivity differentiate AZD3229 from other agents used in GIST treatment.

Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D, AstraZeneca, said: “GIST represents a significant unmet medical need. Through this agreement, the development of AZD3229, a small molecule that inhibits KIT, can be accelerated with the aim of bringing a new treatment to patients faster.”

“We are very pleased to enter this global exclusive license agreement with AstraZeneca and look forward to working with medical experts and global regulatory agents to advance this promising investigational medicine,” commented Dr. Zhenhai Shen, Tai Kang’s authorized representative.

Under the agreement, AstraZeneca will receive an upfront payment and milestone-based payments linked to clinical, regulatory and commercial successes, as well as royalty payments.

About AZD3229

AZD3229 is small molecule inhibitor of KIT and PDGFR α discovered and developed by AstraZeneca. It has the potential to be best-in-class based on preclinical data showing efficacy and a favorable safety profile.

About Ningbo Tai Kang Medical Technology Co. Ltd.

Ningbo Tai Kang Medical Technology Co. Ltd. is an oncology focused biopharma company based in China with global development capabilities in advancing clinical stage assets.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191108005293/en/

CONTACT: Ms.Mingyuan Yuan




SOURCE: Ningbo Tai Kang Medical Technology Co. Ltd.

Copyright Business Wire 2019.

PUB: 11/08/2019 09:00 AM/DISC: 11/08/2019 09:01 AM


© 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Humidity: 51%
Winds: S at 11mph
Feels Like: 26°

Your Extended Forecast


High 57°/Low 34°
Mix of sun and clouds. Highs in the upper 50s and lows in the mid 30s.


High 54°/Low 32°
Abundant sunshine. Highs in the mid 50s and lows in the low 30s.


High 63°/Low 37°
Sunshine. Highs in the low 60s and lows in the upper 30s.
Online Features

Pet Central


Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>



Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>



Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>



Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>

  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.